

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Creamer Victoria L</u> _____ (Last) (First) (Middle) <u>251 BALLARDVALE STREET</u> _____ (Street) <u>WILMINGTON MA 01887</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>10/20/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [CRL]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP & Chief People Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>5,879⁽¹⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Options (Right to Buy)</u>	<u>02/01/2020</u>	<u>02/01/2024</u>	<u>Common Stock</u>	<u>4,290⁽²⁾</u>	<u>124.13</u>	<u>D</u>	
<u>Stock Options (Right to Buy)</u>	<u>02/22/2020</u>	<u>02/22/2024</u>	<u>Common Stock</u>	<u>6,761⁽³⁾</u>	<u>144.67</u>	<u>D</u>	
<u>Stock Options (Right to Buy)</u>	<u>05/29/2021</u>	<u>05/29/2030</u>	<u>Common Stock</u>	<u>5,571⁽⁴⁾</u>	<u>179.66</u>	<u>D</u>	

Explanation of Responses:

- Consists of: (a) 754 shares of common stock; (b) 5,125 unvested restricted stock units which vest as follows: 755 on Feb 1, 2021, 397 on Feb 22, 2021, 417 on May 9, 2021, 755 on Feb 1, 2022, 396 on Feb 22, 2022, 418 on May 29, 2022, 755 on Feb 1, 2023, 397 on Feb 22, 2023, 417 on May 29, 2023 and 418 on May 29, 2024.
- 1,072 Stock Options have vested as of the reporting date. The remaining 3,218 stock options will vest as follows: 1,073 on Feb 1, 2021, 1,072 on Feb 1, 2022 and 1,073 on Feb 1, 2023.
- 1,690 Stock Options have vested as of the reporting date. The remaining 5,071 stock options will vest as follows: 1,690 on Feb 22, 2021, 1,690 on Feb 22, 2022 and 1,691 on Feb 22, 2023.
- Stock Options will vest as follows: 1,392 on May 29, 2021, 1,393 on May 29, 2022, 1,393 on May 29, 2023 and 1,393 on May 29, 2024.

/s/ Victoria L. Creamer

10/28/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.